瑞舒伐他汀联合恩替卡韦治疗慢性乙型肝炎合并脂肪肝的疗效观察

摘要

目的 观察瑞舒伐他汀联合恩替卡韦治疗慢性乙型肝炎合并脂肪肝的疗效.方法 入选58 例慢 性乙型肝炎合并脂肪肝的患者随机分为治疗组(30 例)和对照组(28 例).对照组给予恩替卡韦治疗48 周,治疗 组相同给予恩替卡韦治疗的情况下,在第12~24 周每晚加服瑞舒伐他汀联合治疗.两组均给予基础对症支持治 疗,疗程为48 周.在治疗前、治疗后的各个时间点检测血清ALT水平、HBV-DNA、甘油三酯(TG)、总胆固醇(TC)、LDL-C、HDL-C进行比较.结果 两组肝功能指标、HBV DNA、血清ALT水平均有改善,其中治疗组的血清ALT 水平、TC、TG、LDL-C、HDL-C的改善明显优于对照组(P<0.05).结论 瑞舒伐他汀联合恩替卡韦治疗慢性乙型 肝炎合并脂肪肝的患者在血清ALT水平改善上有明显效果,对于脂肪肝疗效显著,且不良反应少.%Objective To study the therapeutic efficacy of rosuvastain combined with entecavir for treating patients of chronic hepatitis B (CHB) complicated with fatty liver. Methods Fifty-eight patients of chronic hepatitis B complicated with fatty liver were randomly assigned into two groups. The control group (n=28) was treated by entecavir for 48 weeks, and the study group (n=30) applied rosuvastatin every night from the 12th to 24"' week based on the control group. The serum ALT, HBV-DNA, TG, TC, LDL-C, and HDL-C of the patients before and after treatment were compared. Results The indices of liver function, HBV-DNA, serum ALT of the two group were improved significantly (P<0.05), and the improvement of serum ALT, TG, TC, LDL- C, HDL-C of the study group was significantly better than that of the study group (P<0.05). Conclusion For treating patients of chronic hepatitis B complicated with fatty liver, rosuvastain combined with entecavir has significant effect in improving serum ALT, with fewer side effects.